
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is supported by a powerful combination of accelerating oncology diagnostics, a fast-growing data platform, and a widening AI-enabled moat, with 3Q26 revenue of $411.5M rising 23.1% YoY and full-year FY2026 revenue guided to $1,600-1,605M. Its fundamentals are strengthened by 32% YoY oncology testing growth, 33% YoY data and applications growth, record data-licensing bookings above $550M year-to-date, and improving profitability, as adjusted EBITDA reached $25.6M while FY2026 EBITDA guidance was maintained at about $65M. The company also has multiple self-funding growth catalysts, including xT CDx pricing migration, xF and MRD reimbursement upside, and the planned Personalis acquisition, which should deepen revenue visibility and expand exposure to a larger MRD market.
Bears say
Tempus AI is facing a negative fundamental setup because its diagnostics business appears exposed to execution and focus risks tied to its commercial partner, while its revenue visibility is weakened by highly variable pharma ordering patterns and budgets that can shift quarter-to-quarter as priorities change. The company also faces uncertainty around ordering frequency and funding from the U.S. Department of Veterans Affairs for the Million Veteran Program, adding another layer of instability to demand and near-term operating performance. In addition, the possibility that Tempus’s deal to acquire PSNL might not close could force PSNL to increase spending and investment, which would underscore capital intensity and integration risk rather than durable fundamental strength.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Tempus AI Inc (TEM) Forecast
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares